Matthew Luchini
Stock Analyst at BMO Capital
(2.05)
# 3,017
Out of 5,154 analysts
35
Total ratings
44.44%
Success rate
6.45%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Luchini
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Maintains: Outperform | $51 → $30 | $8.07 | +271.75% | 4 | Mar 18, 2022 | |
| JSPR Jasper Therapeutics | Initiates: Outperform | $190 | $1.38 | +13,668.12% | 1 | Oct 20, 2021 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $89 → $69 | $20.07 | +243.80% | 3 | Sep 10, 2021 | |
| KOD Kodiak Sciences | Maintains: Market Perform | $138 → $104 | $24.86 | +318.34% | 3 | May 11, 2021 | |
| CCCC C4 Therapeutics | Initiates: Outperform | $55 | $3.04 | +1,709.21% | 1 | Mar 31, 2021 | |
| ARVN Arvinas | Initiates: Outperform | $101 | $13.60 | +642.65% | 2 | Mar 31, 2021 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $630 | $759.86 | -17.09% | 13 | Jan 25, 2021 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Market Perform | $119 → $124 | $432.83 | -71.35% | 2 | Nov 6, 2020 | |
| GILD Gilead Sciences | Maintains: Market Perform | $74 → $64 | $143.93 | -55.53% | 2 | Oct 29, 2020 | |
| VKTX Viking Therapeutics | Initiates: Outperform | $14 | $32.98 | -57.55% | 1 | Jun 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $47 → $60 | $1.13 | +5,209.73% | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $28 → $14 | $13.16 | +6.38% | 1 | Aug 15, 2018 |
Replimune Group
Mar 18, 2022
Maintains: Outperform
Price Target: $51 → $30
Current: $8.07
Upside: +271.75%
Jasper Therapeutics
Oct 20, 2021
Initiates: Outperform
Price Target: $190
Current: $1.38
Upside: +13,668.12%
Apellis Pharmaceuticals
Sep 10, 2021
Maintains: Outperform
Price Target: $89 → $69
Current: $20.07
Upside: +243.80%
Kodiak Sciences
May 11, 2021
Maintains: Market Perform
Price Target: $138 → $104
Current: $24.86
Upside: +318.34%
C4 Therapeutics
Mar 31, 2021
Initiates: Outperform
Price Target: $55
Current: $3.04
Upside: +1,709.21%
Arvinas
Mar 31, 2021
Initiates: Outperform
Price Target: $101
Current: $13.60
Upside: +642.65%
Regeneron Pharmaceuticals
Jan 25, 2021
Upgrades: Outperform
Price Target: $630
Current: $759.86
Upside: -17.09%
Madrigal Pharmaceuticals
Nov 6, 2020
Maintains: Market Perform
Price Target: $119 → $124
Current: $432.83
Upside: -71.35%
Gilead Sciences
Oct 29, 2020
Maintains: Market Perform
Price Target: $74 → $64
Current: $143.93
Upside: -55.53%
Viking Therapeutics
Jun 5, 2020
Initiates: Outperform
Price Target: $14
Current: $32.98
Upside: -57.55%
Dec 3, 2019
Downgrades: Market Perform
Price Target: $47 → $60
Current: $1.13
Upside: +5,209.73%
Aug 15, 2018
Maintains: Market Perform
Price Target: $28 → $14
Current: $13.16
Upside: +6.38%